These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
    Author: Chen J, Schmitt A, Bunjes D, Chen B, Schmitt M.
    Journal: Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013.
    Abstract:
    Recently, we described the receptor for hyaluronic acid-mediated motility (RHAMM) as a leukemia-associated antigen and characterized the RHAMM-derived peptide R3 (pos. 165-173: ILSLELMKL) as a CD8+ T cell epitope. Directing CD8+ T lymphocytes specifically to R3 might help to shape the graft-versus-leukemia effect observed after allogeneic stem cell transplantation (allo-SCT). To detect the potential induction of R3-specific cytotoxic T lymphocytes in chronic myeloid leukemia (CML) patients after allo-SCT and healthy donors, we used mixed lymphocyte peptide culture, enzyme-linked immunospot (ELISPOT) release assays for interferon (IFN)-gamma and granzyme B, tetramer staining and 51Cr release cytotoxicity assays. The R3 peptide showed the capacity to elicit specific CD8+ T cell responses characterized by the release of IFN-gamma and granzyme B upon stimulation with R3-pulsed T2 cells. Responses to R3 peptide were detected in 67% (6/9) of the CML patients after allo-SCT and 24% (8/34) of healthy donors in ELISPOT assays for IFN-gamma and granzyme B. These R3-specific CD8+ T cells comprised predominantly effector cells (CCR7-CD45RA+ or CD27-CD45RA+) in patients with CML after allo-SCT or healthy donors respectively. Cytotoxicity assays demonstrated effective lysis of CML progenitor cells by R3-primed CD8+ T lymphocytes. Imatinib inhibited the functional activation of R3-specific CD8+ T lymphocytes. In summary, we demonstrated R3-specific CD8+ effector T lymphocytes after allo-SCT in CML patients which might have been augumented by R3 peptide vaccination and hampered at least partially by imatinib in this particular patient cohort.
    [Abstract] [Full Text] [Related] [New Search]